Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: Carolin M. Lieber Clear advanced filters

  • There is limited data on how SARS-CoV-2 antivirals compare regarding efficacy and blocking transmission. Here, treating dwarf hamsters and ferrets with either molnupiravir or paxlovid the authors find comparable efficacy against severe COVID-19-like disease and complete block of transmission by molnupiravir.

    • Robert M. Cox
    • Carolin M. Lieber
    • Richard K. Plemper
    ResearchOpen Access
    Nature Communications
    Volume: 14, P: 1-14

  • Molnupiravir was the first orally available SARS-CoV-2 antiviral approved for outpatient use against SARS-CoV-2, but its efficacy against variants of concern, especially delta, was questioned. Here the authors evaluate molnupiravir against variant of concern in numerous models, including human airway epithelium organoids, ferrets and Roborovski dwarf hamsters.

    • Carolin M. Lieber
    • Robert M. Cox
    • Richard K. Plemper
    ResearchOpen Access
    Nature Communications
    Volume: 13, P: 1-13

  • In this study, the authors report the small molecule inhibitor EDP-235 as a potent inhibitor of SARS-CoV-2 and show that it is effective against a range of variants and other coronaviruses and that it suppresses virus replication, reduces lung damage, and prevents transmission in small animal models.

    • Michael H. J. Rhodin
    • Archie C. Reyes
    • Yat Sun Or
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-12

  • Measles virus infection causes immunosuppression and it’s unclear whether this can be prevented by antivirals. Here, using a canine distemper virus ferret model, the authors show that measles-like immune amnesia and lethal exacerbated respiratory disease after consecutive respiratory virus infections can be mitigated by oral antiviral therapy initiated at the onset of primary clinical signs.

    • Robert M. Cox
    • Josef D. Wolf
    • Richard K. Plemper
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-16

  • Remdesivir is an approved antiviral treatment for COVID-19, but it needs to be administered intravenously. Here, Cox et al. show that GS-621763, a prodrug of remdesivir parent nucleoside GS-441524 has good oral bioavailability and inhibits SARS-CoV-2 and variants of concerns in ferrets.

    • Robert M. Cox
    • Josef D. Wolf
    • Richard K. Plemper
    ResearchOpen Access
    Nature Communications
    Volume: 12, P: 1-11

  • The Somatic Mosaicism across Human Tissues Network aims to create a reference catalogue of somatic mosaicism across different tissues and cells within individuals.

    • Tim H. H. Coorens
    • Ji Won Oh
    • Yuqing Wang
    Reviews
    Nature
    Volume: 643, P: 47-59